Cmpx stock forecast.

LCTX is expected to report earnings to rise 3.50% to -4 cents per share on March 14. The last earnings report on November 09 showed earnings per share of -3 cents, beating the estimate of -5 cents. With 284.08K shares outstanding, the current market capitalization sits at 169.46M.CMPX Stock Predictions. CMPX Stock Buy or Sell? - Get a free CMPX stock trend analysis report to help you analyze and make a better CMPX stock predictions. The stock analysis service is provided by MarketClub, using their Smart Scan and Trade Triangle technology. It uses technical analysis and the current market condition to give you the best ...The Meme Stock. C-Suite Advisors. Sign In. ... Nvidia earnings crush forecasts, outlook tops estimates, amid surging AI demand. By Martin Baccardax. Nov 21, 2023 5:00 PM EST. STOCKS. MSFT NVDA.When is Compass Therapeutics's earnings date? Compass Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 20th, 2024 based off last year's report dates. Learn more on CMPX's earnings history.

BHC Stock 12 Months Forecast. $9.00. (30.72% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is $9.00 with a high forecast of $16.00 and a low forecast of $6.00. The average price target represents a 30.72% change from the last price of $6.89.

A high-level overview of CompX International Inc. (CIX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Stock price analysis for Compass Therapeutics, Inc. (CMPX), stock quote, stock research, rsi, macd, support, resistance and most important highlights.NSD:CMPX Detailed Stock Analysis, Stock Price Forecasts, Analyst Ratings, Financial Analysis, Stock News & Historic Quotes Abstract. Biogenic secondary organic aerosols (SOAs) contribute to a large fraction of fine aerosols globally, impacting air quality and climate. The formation of biogenic SOA depends on not only emissions of biogenic volatile organic compounds (BVOCs) but also anthropogenic pollutants including primary organic aerosol, sulfur dioxide (SO2), …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

Website. 2014. 26. Tom Schuetz. https://www.compasstherapeutics.com. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company’s product candidates include CTX-009, a bispecific antibody that blocks Delta …

Compass Therapeutics Stock (NASDAQ: CMPX) stock price, news, charts, stock research, profile. ... Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast. Lisa Levin - Jan 24, ...

Stock analysis for CompX International Inc (CIX:NYSEAmerican) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Predictions of CMPX stock price for tomorrow.US Stock MarketDetailed Quotes. PEPG PepGen. Close 11/13 16:00 ET. 4.340. +0.480 +12.44%. High 4.762 ... Inc. (PEPG), 4D Molecular Therapeutics (FDMT) and ...Dec 1, 2023 · When is Compass Therapeutics's earnings date? Compass Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 20th, 2024 based off last year's report dates. Learn more on CMPX's earnings history. Looking ahead, revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Metals and Mining industry in …Abstract. Biogenic secondary organic aerosols (SOAs) contribute to a large fraction of fine aerosols globally, impacting air quality and climate. The formation of biogenic SOA depends on not only emissions of biogenic volatile organic compounds (BVOCs) but also anthropogenic pollutants including primary organic aerosol, sulfur dioxide (SO2), …

Get actionable alerts from top Wall Street Analysts. Find out before anyone else which stock is going to shoot up. Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. Get the latest Apexigen APGN Stock forecast and financial predictions, including earnings and sales forecast, on TipRanks.com.Compass Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of …10% most volatile stocks in GB Market. 12.0%. 10% least volatile stocks in GB Market. 2.6%. Stable Share Price: CPX is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 12% a week. Volatility Over Time: CPX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.Oct 2, 2023 · Future criteria checks 0/6. Compass Therapeutics is forecast to grow earnings and revenue by 21.6% and 76.7% per annum respectively while EPS is expected to grow by 25.3% per annum. CMPX stock forecast Our latest prediction for Compass Therapeutics Inc's stock price was made on the March 15, 2023 when the stock price was at 3.56$. In the short term (2weeks), CMPX's stock price should underperform the market by -2.94%. During that period the price should oscillate between -8.72% and +5.46%.What this means: InvestorsObserver gives Compass Therapeutics Inc. (CMPX) an overall rank of 34, which is below average. Compass Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.The value each CMPX share was expected to gain vs. the value that each CMPX share actually gained. Compass Therapeutics ( CMPX) reported Q2 2023 earnings per share (EPS) of -$0.09, missing estimates of -$0.08 by 9.30%. In the same quarter last year, Compass Therapeutics 's earnings per share (EPS) was -$0.08. Compass Therapeutics is expected to ...

F5 Inc. -0.42%. $9.16B. CALX | Complete Calix Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Compass Therapeutics, Inc. - Hold. Zacks' proprietary data indicates that Compass Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CMPX shares ...

Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compx International, Inc. - Class A share forecasts, stock quote and buy / sell signals below. According to present data Compx International, Inc. - Class A's CIX shares and potentially its market environment have been in a bullish cycle in the last 12 months ...The Compass Therapeutics stock forecast for tomorrow is $ 1.516608, which would represent a -1.52% loss compared to the current price. In the next week, the price of CMPX is expected to decrease by -2.77% and hit $ 1.497361. As far as the long-term Compass Therapeutics stock forecast is ...Compass Therapeutics Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time CMPX stock price.Find the latest Compass Therapeutics, Inc. CMPX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range investment ratingCompass pointing South. CMPX We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statisti We are not in the business of getting …Back to CMPX Overview. *The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once ...Aeterna Zentaris (TSE:AEZS) Forecast: Is this specialty biopharmaceutical company a good stock to buy? Find out the latest analysis, ratings, and price targets from TipRanks, the leading platform for financial insights.March 7, 2024. EPS forecast (this quarter) $0.30. Annual revenue (last year) $378.5M. Annual profit (last year) $18.7M. Net profit margin. Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments. Get the latest Compass Therapeutics, Inc. (CMPX) stock news and headlines to help you in your trading ...

Find the latest performance data chart, historical data and news for NASDAQ Composite Index (COMP) at Nasdaq.com.

CMPX Stock 12 Months Forecast. $10.50. (510.47% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $10.50 with a high forecast of $11.00 and a low forecast of $10.00. The average price target represents a 510.47% change from the last price of $1.72.

SOS Limited - ADR Stock Forecast, SOS stock price prediction. Price target in 14 days: 4.203 USD. The best long-term & short-term SOS Limited - ADR share price ... Predicting variations in stock price index has been an important application area of machine learning research. Due to the non-linear and complex nature of the stock market making predictions on stock price index is a challenging and non-trivial task. Deep learning approaches have become an important method in modeling complex relationships in …The 6 analysts offering 1 year price forecasts for CMPX have a max estimate of — and a min estimate of —. Analyst rating Based on 6 analysts giving stock ratings to CMPX in the past 3 months.COMPX REPORTS THIRD QUARTER 2023 RESULTS. Dallas, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- CompX International Inc. (NYSE American: CIX) announced today sales of $40.3 million for the third quarter of 2023 compared to $42.9 million in the sam... 24 days ago - GlobeNewsWire.PAYO Stock 12 Months Forecast. $8.80. (56.58% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Payoneer in the last 3 months. The average price target is $8.80 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 56.58% change from the last price of $5.62.Stock Screener; ETF Screener; Comparisons; Explore Alpha Picks ... Compass Therapeutics (CMPX) Investor Presentation - Slideshow. Nov. 23, 2022 6:22 AM ET Compass Therapeutics, Inc. (CMPX) SA ...Compass Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CMPX updated stock price target summary.Buy a little, but exit at $42.25. (CPX-T) They successfully transitioned from coal to gas and other green energy. An excellent long-term performer, but 27% over 3 years. Was up last year in a down year. (CPX-T) Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Business sensitive to Alberta market.

The ALX Oncology Holdings Inc. stock price fell by -4.02% on the last day (Friday, 24th Nov 2023) from $9.21 to $8.84. During the last trading day the stock fluctuated 10.18% from a day low at $8.79 to a day high of $9.69. The price has risen in 6 of the last 10 days and is up by 12.76% over the past 2 weeks.Learn more about Compass Therapeutics, Inc.'s (CMPX) dividend history, ex-dividend date, and yield. Zacks.com Our Research, Your SuccessThe Compass Therapeutics stock forecast for tomorrow is $ 1.516608, which would represent a -1.52% loss compared to the current price. In the next week, the price of CMPX is expected to decrease by -2.77% and hit $ 1.497361. As far as the long-term Compass Therapeutics stock forecast is ... BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023. Instagram:https://instagram. public ai companiesretiring in another countrychina techiwr etf PAYO Stock 12 Months Forecast. $8.80. (56.58% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Payoneer in the last 3 months. The average price target is $8.80 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 56.58% change from the last price of $5.62.According to the issued ratings of 6 analysts in the last year, the consensus rating for Mesoblast stock is Hold based on the current 1 sell rating, 3 hold ratings and 2 buy ratings for MESO. The average twelve-month price prediction for Mesoblast is $7.13 with a high price target of $17.00 and a low price target of $1.50. when does the sphere openapple stock price prediction Learn more about Compass Therapeutics, Inc.'s (CMPX) dividend history, ex-dividend date, and yield. Zacks.com Our Research, Your SuccessDec 1, 2023 · The stock of Compass Therapeutics Inc (CMPX) has gone down by -4.07% for the week, with a -8.33% drop in the past month and a -29.18% drop in the past quarter. The volatility ratio for the week is 4.13%, and the volatility levels for the past 30 days are 7.49% for CMPX. The simple moving […] what is the value of a brick of gold CMPX Stock 12 Months Forecast. $10.50. (510.47% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $10.50 with a high forecast of $11.00 and a low forecast of $10.00. The average price target represents a 510.47% change from the last price of $1.72.Compass Therapeutics (CMPX) Stock Forecast & Price Prediction. Estimation of the future price movement of Compass Therapeutics stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions. CMPX : 3.36 (+8.74%) Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Globe Newswire - Mon Mar 21, 2022. Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced...